523642

PI Industries Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by M/s. Makarand M. Joshi & Co., confirms that the company has complied with applicable SEBI Regulations and circulars/guidelines. No significant non-compliances, actions by SEBI or Stock Exchanges, or resignations of statutory auditors were observed during the review period.

PI Industries Limited has intimated about upcoming interactions with analysts and investors. The company will hold one-on-one meetings in Mumbai with Matthews International Capital Management on May 31, 2026, ICICI Prudential Asset Management Company on June 01, 2026, and ithought PMS on June 09, 2026. No unpublished price sensitive information is proposed to be shared during these meetings.

PI Industries Limited will hold one-on-one interactions with investors/analysts from Matthews International Capital Management (May 31, 2026), ICICI Prudential Asset Management Company (June 01, 2026), and ithought PMS (June 09, 2026) in Mumbai. No unpublished price sensitive information will be shared during these meetings.

PI Industries Limited announced its schedule for interactions with analysts and institutional investors under Regulation 30(6) of SEBI (LODR) Regulations. The company will hold one-on-one meetings on May 31, June 01, and June 09, 2026, with Matthews International Capital Management, ICICI Prudential Asset Management Company, and ithought PMS, respectively, in Mumbai. The company confirmed that no unpublished price sensitive information will be shared during these meetings.

PI Industries reported FY26 consolidated revenue of ₹67,137 million with a healthy 25% EBITDA margin, supported by 40% growth in Pharma and over 20% in Biologicals, maintaining a debt-free balance sheet. For FY27, management guided for positive revenue growth, driven by recovery in AgChem exports (H2 FY27) and new product launches, including their first homegrown NCE, Pioxaniliprole. Capex is projected at ₹700-800 crore. The company targets ₹500-600 crore top line for Pharma to turn EBITDA positive in 2-3 years and $100 million revenue from Electronic Chemicals in 4-5 years, alongside significant growth from new biological products. Rajnish Sarna stepped down as JMD for health reasons but continues as a Non-Executive Director.

PI Industries Limited announced upcoming interactions with analysts and investors. The company will participate in the Axis Capital Rising Stars Conference 2026 on June 1, 2026, and Citi's 2026 India Conference on June 5, 2026. These meetings will include one-on-one and group interactions at Grand Hyatt, Mumbai. The company confirmed that no unpublished price sensitive information will be shared.

PI Industries Limited will hold interactions with analysts and investors at the Axis Capital Rising Stars Conference 2026 on June 1, 2026, and Citi's 2026 India Conference on June 5, 2026. Both events will take place at Grand Hyatt, Mumbai, involving a mix of one-on-one and group meetings. The company has stated that no unpublished price sensitive information will be shared during these interactions.

ICICI Prudential Mutual Fund increased its shareholding in PI Industries Ltd. through open market acquisitions. The Fund acquired a net of 30,90,753 shares between October 1, 2025, and May 20, 2026, including 4,38,842 shares on May 20, 2026. This increased their total holding from 5.120% (as per the October 1, 2025 disclosure) to 7.157% of the paid-up capital (1,08,58,536 shares). The acquisition is for investment purposes, not seeking controlling interest.

New Filing detected. See link for details.

PI Industries Limited announced the audio recording of its Earnings Conference Call with Analysts and Investors, held on May 20, 2026. The call discussed the Audited Standalone & Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The recording is available on the company's website for investor access.

Standalone Revenue ₹13,914Mn vs ₹16,482Mn (▼15.58% YoY), EBITDA ₹3,852Mn vs ₹5,039Mn (▼23.56% YoY), PAT ₹1,978Mn vs ₹3,858Mn (▼48.73% YoY). EBITDA Margin 27.68% vs 30.57% (▼289bps). The Board also recommended a final dividend of Rs. 10/- per share, bringing the total dividend for FY26 to Rs. 15/- per share. An impairment loss of ₹1,100 million was recognized as an exceptional item. Mr. Arvind Singhal, a Non-Executive, Non-Independent Director, will not seek re-appointment and will retire at the ensuing AGM.

PI Industries Limited announced that its Board has authorized Dr. Atul Kumar Gupta (Whole-Time Director), Mr. Sanjay Agarwal (Group Chief Financial Officer and Head - Strategy and Integrated Development Cell), and Ms. Shruti Joshi (Company Secretary and Compliance Officer) as Key Managerial Personnel. These KMPs are empowered to determine the materiality of an event or information and to make appropriate disclosures to the Stock Exchanges, as per Regulation 30(5) of SEBI Listing Regulations.

Standalone Revenue ₹1,391.4Cr vs ₹1,648.2Cr (▼16% YoY), EBITDA ₹273.5Cr vs ₹503.9Cr (▼46% YoY), PAT ₹197.8Cr vs ₹385.8Cr (▼49% YoY). EBITDA Margin 20% vs 31% (▼1091bps). An exceptional impairment loss of ₹111.7Cr was recorded. A final dividend of ₹10/share was recommended, totaling ₹15/share for FY2025-26. Mr. Rajnish Sarna resigned as JMD but was re-designated as Non-Executive, Non-Independent Director. Mr. Arvind Singhal, Non-Executive, Non-Independent Director, will retire and not seek re-appointment.

Standalone Revenue ₹1391.4Cr vs ₹1648.2Cr (▼15.58% YoY), EBITDA ₹456.3Cr vs ₹572.1Cr (▼20.23% YoY), PAT ₹197.8Cr vs ₹385.8Cr (▼48.73% YoY). EBITDA Margin 32.79% vs 34.71% (▼192bps). The company also recommended a final dividend of Rs. 10/- per share for FY2025-26, bringing the total dividend to Rs. 15/- per share for the year.

Standalone Revenue ₹13,914Mn vs ₹16,482Mn (▼15.6% YoY), EBITDA ₹3,852Mn vs ₹5,039Mn (▼23.6% YoY), PAT ₹1,978Mn vs ₹3,858Mn (▼48.7% YoY). EBITDA Margin 27.7% vs 30.6% (▼290bps). Additionally, the Board recommended a final dividend of ₹10/- per share for FY26, bringing the total to ₹15/-. Mr. Rajnish Sarna resigned as Joint Managing Director, and the company recognized a ₹1,100Mn impairment provision on an equity investment in a subsidiary due to business losses.

Standalone Revenue ₹1,391.4 Cr vs ₹1,648.2 Cr (▼15.6% YoY), EBITDA ₹273.5 Cr vs ₹503.9 Cr (▼45.7% YoY), PAT ₹197.8 Cr vs ₹385.8 Cr (▼48.7% YoY). EBITDA Margin 19.66% vs 30.57% (▼1091bps). The Board also recommended a final dividend of ₹10/- per share, making the total dividend for FY26 ₹15/- per share. Mr. Rajnish Sarna resigned as Joint Managing Director but was re-designated as Non-Executive, Non-Independent Director, and Mr. Arvind Singhal (Non-Executive, Non-Independent Director) will retire at the AGM.

PI Industries Limited reported Standalone financial results for Q4 FY26. Standalone Revenue ₹13,914Mn vs ₹16,482Mn (▼15.58% YoY), EBITDA ₹3,852Mn vs ₹5,039Mn (▼23.56% YoY), PAT ₹1,978Mn vs ₹3,858Mn (▼48.73% YoY). EBITDA Margin 27.68% vs 30.57% (▼289bps). The Board recommended a final dividend of ₹10 per share, making the total dividend for FY26 ₹15 per share. Mr. Rajnish Sarna resigned as Joint Managing Director but was re-designated as Non-Executive, Non-Independent Director. The company recognized a significant provision of ₹1,100 million for impairment on an equity investment due to business losses. Various director appointments/re-appointments and cost auditor re-appointment were also approved.

Standalone Revenue ₹13,914Mn vs ₹16,482Mn (▼15.6% YoY), EBITDA ₹3,852Mn vs ₹5,039Mn (▼23.6% YoY), PAT ₹1,978Mn vs ₹3,858Mn (▼48.7% YoY). EBITDA Margin 27.7% vs 30.6% (▼290bps). The results were impacted by an exceptional impairment loss of ₹1,117Mn on an equity investment. The Board recommended a final dividend of ₹10/- per share. Mr. Rajnish Sarna resigned as Joint Managing Director but was re-designated as Non-Executive, Non-Independent Director.